Add Glucokinase Activator to Target A1c

Inclusion Criteria: * A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening. * On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at least 1000 mg once daily. * Males, females of childbearing potential (must have a negative pregnancy test and be willing to comply with protocol contraception), and females of non-childbearing potential. * Age 18 to 75 years, inclusive, at the time of screening. * HbA1c ≥7.0% and ≤9.5%. * Generally stable health without active infection or history of major surgery or significant injuries within the last year. Exclusion Criteria: * Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis. * Clinically significant abnormal lab values including eGFR \<50ml/min/1.73m2, ALT, bilirubin or AST \>1.5 X ULN, hypokalemia or other clinically significant electrolyte abnormality. * History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack within 2 years of screening. * Presence of symptomatic congestive heart failure. * History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or devices during the last 2 years or any history of atrial fibrillation or flutter beyond a single short-term episode (e.g., lasting 1-2 days). * History or presence of a 2nd degree or greater atrioventricular block in the absence of a pacemaker. * A 12-lead ECG, from screening or baseline demonstrating QTcF interval \>450 msec for males or \>47 msec for females. * A family or personal history of long QT syndrome. * History of pancreatitis. * Persistent, uncontrolled hypertension. * Presence of chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic steatohepatitis \[NASH\]) and/or known liver cirrhosis. * Participation in any formal weight loss program, or fluctuation of \> 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening. * A positive pre-study drug screen. * Participation in a clinical trial and receipt of an investigational product within 30 days. * Have a history of drug abuse within 2 years of screening or a positive pre-screen drug screen. * Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening. * A history of excessive alcohol consumption within the last 2 years prior to screening * Mental or legal incapacitation. * Blood donation of approximately 1 pint (500 mL) within 8 weeks. * History of MEN-2 or family history of medullary thyroid cancer. * History of cancer, other than non-melanoma skin cancer, that required therapy in the 5 years prior study start.